Neurocognitive performance in myelin oligodendrocyte glycoprotein antibody-associated disease: A systematic review
Helvécio N Feitosa Filho1, João Filipe Cavalcante Uchoa Furtado1, Eduardo Correia Eulálio1
1School of Medicine, University of Fortaleza, Ceará, Brazil.
Introduction:
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating disorder of the central nervous system. Although motor and visual outcomes are established, cognitive effects remain unclear. This systematic review and meta-analysis assessed standardized neuropsychological tests to define the cognitive profile of MOGAD.
Methods:
A comprehensive search of PubMed, Embase, and Web of Science up to August 15, 2025, identified 11 observational studies including 507 patients (68 pediatric, 439 adults). Extracted data included patient characteristics, treatments, and outcomes from validated cognitive instruments such as the Montreal Cognitive Assessment (MoCA), Paced Auditory Serial Addition Test (PASAT-2 and PASAT-3), Symbol Digit Modalities Test (SDMT), and the Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V).
Results:
Adults with MOGAD showed mild global cognitive impairment, with pooled MoCA scores of 24.69 (95 % CI: 23.31-26.07). Processing speed and working memory were consistently affected, with pooled PASAT-3 means of 39.14 (95 % CI: 35.68-42.61), PASAT-2 of 30.91 (95 % CI: 28.08-33.75), and SDMT of 44.47 (95 % CI: 41.73-47.20). In pediatric cohorts, WISC-V scores suggested relative preservation of most domains (VCI: 95.57, VSI: 98.31, FRI: 106.14, WMI: 97.44, PSI: 96.66, FSIQ: 98.93).
Conclusion:
This meta-analysis shows that cognitive impairment is a heterogeneous but relevant feature of MOGAD, most evident in processing speed and working memory. Standardized cognitive testing should be integrated into care, and longitudinal studies are needed to clarify long-term outcomes.
More Related Videos
10:19High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
08:03Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
Published on: April 15, 2014
Related Concept Videos
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...